Targeting the FGFR Pathway in Patients with Advanced Solid Tumors

In the phase II FUZE trial targeting the FGFR pathway, Debio 1347 showed limited antitumor activity and manageable toxicity in patients with advanced solid tumors. Results from transcriptome-based analysis enhanced our understanding of the genomic landscape of FGFR fusion–driven tumors, informing clinical trial design and generating hypotheses for resistance mechanisms.

See related article by Grivas et al., p. XX.